Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpointsThe DIRECTION trial results show ...

Ipsen initiates a new share buy-back program PARIS, FRANCE, 18 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today ...

The 50ng dose of corabotase will undergo further evaluation in the Phase III LAURITE programme.

Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are ...

An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, ...

The key piece of the acquisition is Tazverik, a third-line treatment for follicular lymphoma. While that drug is the first in a class of therapies that treats cancer by targeting a particular enzyme ...

After a lengthy strategic review, Ipsen’s plan to hive off its consumer health care (CHC) business is gaining traction. With the blessing of its board of directors, Ipsen entered exclusive talks with ...

Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNITM, as ...

Imagine going to work every day knowing that what you do directly contributes to improving the lives of people with rare and life-limiting conditions. That’s what life is like for Bénédicte ...

Evolution of the composition of the Board of Directors PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) ...

According to deal terms announced Monday, Paris-based Ipsen will pay Exicure $20 million up front to begin the alliance. In exchange, Ipsen gains exclusive options to license the Huntington’s disease ...

Cash and cash equivalents totaled €136.1 million as of March 31, 2026€9.6 million in revenue for the first three months of 2026, from royalties ...